Mostrar el registro sencillo del ítem

Artículo

dc.creatorPaz Ares, Luises
dc.creatorRamalingam, Suresh S.es
dc.creatorCiuleanu, Tudor Eliadees
dc.creatorLee, Jong Seokes
dc.creatorUrban, Laszloes
dc.creatorBernabé-Caro, Reyeses
dc.creatorReck, Martines
dc.date.accessioned2022-10-10T18:31:07Z
dc.date.available2022-10-10T18:31:07Z
dc.date.issued2022
dc.identifier.citationPaz Ares, L., Ramalingam, S.S., Ciuleanu, T.E., Lee, J.S., Urban, L., Bernabé-Caro, R. y Reck, M. (2022). First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. Journal of Thoracic Oncology, 17 (20), 289-308. https://doi.org/10.1016/j.jtho.2021.09.010.
dc.identifier.issn1556-0864es
dc.identifier.issn1556-1380es
dc.identifier.urihttps://hdl.handle.net/11441/137788
dc.description.abstractIntroduction: In CheckMate 227, nivolumab plus ipilimu mab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% (primary end point) or less than 1% (prespecified descriptive analysis). We report re sults with minimum 4 years’ follow-up. Methods: Adults with previously untreated stage IV or recurrent NSCLC were randomized (1:1:1) to nivolumab plus ipilimumab, nivolumab, or chemotherapy (PD-L1 1%); or to nivolumab plus ipilimumab, nivolumab plus chemotherapy, or chemotherapy (PD-L1 <1%). Efficacy included OS and other measures. Safety included timing and management of immune-mediated adverse events (AEs). A post hoc analysis evaluated efficacy in patients who dis continued nivolumab plus ipilimumab due to treatment related AEs (TRAEs). Results: After 54.8 months’ median follow-up, OS remained longer with nivolumab plus ipilimumab versus chemo therapy in patients with PD-L1 greater than or equal to 1% (hazard ratio ¼ 0.76; 95% confidence interval: 0.65–0.90) and PD-L1 less than 1% (0.64; 0.51–0.81); 4-year OS rate with nivolumab plus ipilimumab versus chemotherapy was 29% versus 18% (PD-L1 1%); and 24% versus 10% (PD L1 <1%). Benefits were observed in both squamous and nonsquamous histologies. In a descriptive analysis, efficacy was improved with nivolumab plus ipilimumab relative to nivolumab (PD-L1 1%) and nivolumab plus chemotherapy (PD-L1 <1%). Safety was consistent with previous reports. The most common immune-mediated AE with nivolumab plus ipilimumab, nivolumab, and nivolumab plus chemo therapy was rash; most immune-mediated AEs (except endocrine events) occurred within 6 months from start of treatment and resolved within 3 months after, mainly with systemic corticosteroids. Patients who discontinued nivo lumab plus ipilimumab due to TRAEs had long-term OS benefits, as seen in the all randomized population. Conclusions: At more than 4 years’ minimum follow-up, with all patients off immunotherapy treatment for at least 2 years, first-line nivolumab plus ipilimumab continued to demonstrate durable long-term efficacy in patients with advanced NSCLC. No new safety signals were identified. Immune-mediated AEs occurred early and resolved quickly with guideline-based management. Discontinuation of nivolumab plus ipilimumab due to TRAEs did not have a negative impact on the long-term benefits seen in all randomized patients.es
dc.formatapplication/pdfes
dc.format.extent20 p.es
dc.language.isoenges
dc.publisherELSEVIER SCIENCE INCes
dc.relation.ispartofJournal of Thoracic Oncology, 17 (20), 289-308.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPD-1 checkpoint inhibitores
dc.subjectImmunotherapyes
dc.subjectFirst-linees
dc.subjectMetastatic non–small cell lung canceres
dc.subjectCTLA-4es
dc.titleFirst-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Triales
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S155608642103207X?via%3Dihubes
dc.identifier.doi10.1016/j.jtho.2021.09.010es
dc.journaltitleJournal of Thoracic Oncologyes
dc.publication.volumen17es
dc.publication.issue20es
dc.publication.initialPage289es
dc.publication.endPage308es

FicherosTamañoFormatoVerDescripción
First-Line Nivolumab.pdf834.1KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional